Kirkland & Ellis and Zhong Lun advised Yunkang Group Limited on the deal. Herbert Smith Freehills advised CMB International Capital Limited and SPDB International Capital Limited....
Yunkang Group Limited’s $140 Million Hong Kong Listing
Lepu Biopharma’s US$116.1 Million Hong Kong IPO and Listing
Clifford Chance has advised Lepu Biopharma Co., Ltd. on the deal. Herbert Smith Freehills has advised CICC and Morgan Stanley. The Joint Sponsors are CICC and...
Bio-heart Biological Technology Co. Ltd.’s Listing on the Stock Exchange of Hong Kong
Herbert Smith Freehills has advised Huatai Financial Holdings (Hong Kong) Limited. O’Melveny & Myers represented Bio-heart on the deal. Huatai Financial Holdings (Hong Kong) Limited acted...
Brii Biosciences’ US$318 Million Hong Kong IPO
O’Melveny & Myers and Maples and Calder advised Brii Biosciences Limited on the deal. Herbert Smith Freehills has advised Morgan Stanley and UBS. Brii Biosciences Limited...
CARsgen Therapeutics Holdings Limited’s Listing on the Stock Exchange of Hong Kong
Davis Polk and Maples and Calder advised CARsgen Therapeutics Holdings Limited, while Herbert Smith Freehills and Zhong Lun advised Goldman Sachs and UBS on the deal....
Netjoy Holdings Limited’s HK$1.396 Billion Initial Public Offering
Herbert Smith Freehills has advised Haitong International on the deal, while Harneys, DeHeng and Tian Yuan Hong Kong acted as legal counsels to Netjoy Holdings Limited....
Peijia Medical Limited’s Listing On The Hong Kong
Herbert Smith Freehills has advised Morgan Stanley Asia Limited and Huatai Financial Holdings as joint sponsors. O’Melveny & Myers LLP and and Jingtian & Gongcheng advised...